BEEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative. Past performance is a poor indicator of future performance. With a price book ratio of 5.24, BEEM is valued correctly. Do Wall Street analysts like Beam Global more than its competitors Analysts like Beam Global more than other Auto/Tires/Trucks companies. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on or relating to the use of, or inability to use, or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. The average twelve-month price prediction for Beam Global is 26.33 with a high price target of 40.00 and a low price target of 15.00. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. ![]() The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Under no circumstances does any information posted on represent a recommendation to buy or sell a security. Is not operated by a broker, a dealer, or a registered investment adviser. The average price target represents a 233.72 change from the. The firm has four development candidates, which include BEAM-101, BEAM-102, BEAM-201 and BEAM-301. The average price target is 31.67 with a high forecast of 40.00 and a low forecast of 25.00. The Company’s base editing technology of therapeutic applications pursue a suite of both clinically validated and delivery modalities, depending on tissue type, which includes electroporation for delivery to blood cells and immune cells ex vivo lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future, and adeno-associated viral vectors (AAV), for in vivo viral delivery to the eye and potentially other organs. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). ![]() The firm is focused on developing precision genetic medicines based on its base editing technology to provide life-long cures to patients suffering from diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 341 full-time employees. develops and commercializes DNA base editing technologies for the treatment of human disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |